Pandemic Prompts Pause of Patient Enrollment in Fibromyalgia Trial of NYK-2925

Pandemic Prompts Pause of Patient Enrollment in Fibromyalgia Trial of NYK-2925
In response to the COVID-19 pandemic, Aptinyx has temporarily suspended enrollment in its ongoing Phase 2b clinical trial investigating NYX-2925 in women with fibromyalgia. The company, however, has taken measures to make sure that current participants continue receiving the daily treatment. The decision to pause enrollment and continue treatment of previously included patients extends to most of the company's ongoing trials. Only a Phase 2 trial (NCT04044664) of NYX-783 in post-traumatic stress disorder,  which will follow-up patients online, will continue enrolling — as long as it is responsible and practical — the company said in a press release. "Like other life sciences companies, we have had to assess the impact of the evolving COVID-19 pandemic on the enrollment and conduct of our ongoing Phase 2 studies. The health and safety of the patients, clinicians, and colleagues involved in our studies are of the utmost importance to Aptinyx," said Norbert Riedel, PhD, president and CEO of Aptinyx. "Under these unprecedented ci
Subscribe or to access all post and page content.